Adagrasib Improves Survival, Responses in KRASG12C-mutated Advanced NSCLC
DFF332 Elicits Efficacy and Is Safe in Advanced Clear Cell RCC
Neoadjuvant Sacituzumab Govitecan Displays Activity in Muscle-Invasive Bladder Cancer, But Questions Remain
Subcutaneous Amivantamab Shows Noninferior ORR vs IV Formulation in EGFR+ NSCLC